Skip to main
Reviews TB-500

A case-file review of the TB-500 evidence — what the thymosin beta-4 literature actually establishes, where the heptapeptide and the full-length protein get confused, and how compounded access really stands.

EXHIBIT No. 09 // ADD TO THE FILE

Contact Reviews TB-500

Corrections, source suggestions, and editorial questions — the channel for adding to or correcting the record.

Reach the editors

Write to the desk that keeps this casebook for editorial matters: a correction to a TB-500 entry, a peer-reviewed study the record should include, or a question about how a finding was characterized. Every message about the accuracy of the record gets read.

The desk keeps a casebook — it is not a clinic or a pharmacy. It cannot field questions about personal health, dosing, or treatment, and it gives no medical guidance. A message asking for a human dose or a place to buy is outside what these pages do, and it will go unanswered on that count.

What to include

For a correction, the single most useful thing you can send is the citation: the study, the journal, the year, and a DOI or PubMed link. If a claim on the site reads as if it applies to the TB-500 fragment when the underlying study was run on full-length thymosin beta-4, point us to the passage and we will check it against the source.

We aim to keep the file accurate and current, and source suggestions and good-faith corrections are the most direct way to improve it.

Editorial scope

Messages the desk can act on: corrections, citation suggestions, and questions about how the research is framed. Messages it cannot: requests for medical guidance, dosing, prescriptions, or somewhere to buy. Holding that line is part of what keeps this a faithful reading of the literature and not something it was never meant to be.